Synthetic Procedures
Compounds 2 and 3 (synthetic scheme provided in Scheme 1 in manuscript) were synthesized according to Banerjee, R. et al. 1 Pyrimido-indole carboxylic acid derivative (Scheme S1) was synthesized according to Chan, M. et al. 2 2-(piperidin-4-ylmethyl)-3a,4,7,7a-tetrahydro-1H-4,7-epoxyisoindole-1,3(2H)-dione (4). Exo-7-oxabicyclo[2.2.1]hept-5-ene-2,3-dicarboxylic anhydride (3.6 mL, 30.1 mmol) was dissolved in ethanol (30.1 mL). 4-(Aminomethyl) piperidine (3.6 mL, 30.1 mmol) was subsequently added to the solution. The reaction mixture was heated at reflux for 3 h. The mixture was concentrated and dissolved in deionized water. The aqueous layer was washed with dichloromethane (5x). The organic layer was dried with sodium sulfate, filtered, and concentrated. The desired product was a white solid (3.2 g, 40% yield). 1 H NMR (500 MHz, CD 3 OD) δ 6.55 (s, 2H), 5.15 (s, 2H), 3.34 (d, J = 5, 2H), 2.99 (br td, J = 12.5, 3, 2H), 2.92 (s, 2H), 2.49 (td, J = 12.5, 3, 2H), 1.84-1.76 (m, 1H), 1.60 (appar. br d, J = 12.5, 2H), 1 
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Compound 3 (100 mg, 0.31 mmol) was dissolved in anhydrous DMF (1.0 mL). DIPEA (59.2 µL) and 4 (88.2 mg, 0.34 mmol) were subsequently added to the solution. The reaction mixture was heated at 80 °C for 3 h. The mixture was concentrated and purified by column chromatography (100% EtOAc). The product was a light yellow shiny solid (163.3 mg, 95% yield). 1 ). The carboxylic acid derivative 2 (500 mg, 1.4 mmol) was dissolved in anhydrous DMF (2.8 mL). DIPEA (0.49 mL, 2.8 mmol) and pentafluorophenyl triflouroacetate (PFP-TFA) (0.37 mL, 2.1 mmol) were then added. The reaction stirred for 18 h at room temperature and the solution turned dark brown black color. The reaction mixture was concentrated and recrystallized using ethyl acetate to obtain brown, green crystals. The product was confirmed by 1 
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Modified Loxoribine Procedures.
(5-(7-allyl-2-amino-6,8-dioxo-1,6,7,8-tetrahydro-9H-purin-9-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methyl 4-methylbenzenesulfonate (11). To a cooled solution (0 °C) of loxoribine (1 g, 2.9 mmol) in dry pyridine (9.7 mL), a solution of 4-toluenesulfonyl chloride (0.72 g, 3.8 mmol) in dry pyridine (2.5 mL) was added dropwise. The reaction was stirred at 0 °C and was allowed to warm to room temperature for 24 h. The reaction was quenched with methanol (4 mL) and concentrated. The crude mixture was purified using column chromatography (3:5 MeOH: DCM) to provide the product (767 mg, 54% yield). 
Synthesis of Di-agonists Compounds.
CpG_core (12). Followed general procedure for CpG-ODN conjugation. Compound 5 (7.5 mg, 13.5 µmol) was dissolved in anhydrous DMSO (200 µL). The solution was heated at 110 °C for 5 h in a sealed vial. The solution was concentrated and submitted crude. Maleimide-deprotected tricore (27.1 µg, 56 nmol) was dissolved in anhydrous DMSO (40 µL) and treated with CpG-ODN1826 (100 µg, 14 nmol) in PBS (14 µL). The reagents were allowed to react at RT on a shaker for 4 h. The solution was purified by gel electrophoresis. The product band was excised and eluted into HPLC grade water overnight at 37 °C. The solution was concentrated using a 3k centrifugal filter unit (EMD Millipore). The product was confirmed using MALDI-MS and quantified using UV-Vis at 495 nm. . Representative FACS histograms of BMDC IL-12 production when incubated with no agonist (Resting), CpG-ODN, Indole/Lox/CpG, CpG_core, Lox_CpG, Indole_CpG (page S6), Indole_Lox_CpG, Indole_Lox, Indole_core, Lox_core, Loxoribine, and Indole (page S18) at 0.5 µM. BMDCs were incubated with the designated agonist for 6 h at 37 °C and subsequently stained with FITC CD11c and APC IL-12 (ICS). Data was obtained over three independent experiments. S18 Figure S9 . Representative FACS histograms of BMDC IL-12 production when incubated with no agonist (Resting), Indole_Lox_CpG, Indole_Lox_CpG with CLI-095 (100 nM), Indole_Lox_CpG with CpG2088 (100nM), and Indole_Lox_CpG2088 at 0.5 µM. BMDCs were incubated with the designated inhibitor for 1 h at 37 °C and then the designated agonist for an additional 6 h at 37 °C. Cells were subsequently stained with FITC CD11c and APC IL-12 (ICS). Data was obtained over three independent experiments. Figure S10 . Flow Cytometry analysis of IL-12 producing BMDCs when incubated with Indole_Lox_CpG (0.5 µM) and TLR signaling inhibitors, TLR4 inhibitor CLI-095 (100 nM) or TLR9 antagonist CpG-ODN2088 (100 nM) as well as tri-antagonist, Indole_Lox_CpG2088 (0.5 µM). Tri-antagonist (Indole_Lox_CpG2088) exhibited nearly resting level (no agonist) IL-12 cytokine production. BMDCs were incubated with the designated inhibitor for 1 h at 37 °C. Then, the agonist was added and incubated with BMDCs for an additional 6 h at 37 °C. Cells were subsequently stained with FITC CD11c and APC IL-12 (ICS). Data was obtained over three independent experiments. Spectrum displays three measurements (measurement 1-red, 2-green, 3-blue) of a IndoleLox_CpG solution. The measurements showed that two different sized aggregates, comparable to that of CpG-ODN1826, formed in solution with diameters of 106 nm ± 11 and 22.6 nm ± 1.4.
